BioNTech to acquire CureVac, potentially resolving IP overhang ($106.69, +1.23)
FDA seeking input from consumer organizations on Adcom vacancies
Follow-up: BioNTech to acquire CureVac in public exchange offer
Powered by FactSet Research Systems Inc.